Treatment  	Treatment  	 NN	O
of  	of  	 IN	O
multiresistant  	multiresistant  	 FW	B-NP
Gram  	Gram  	 FW	I-NP
positive  	positive  	 FW	I-NP
endocarditis  	endocarditis  	 FW	I-NP
Epidemiology  	Epidemiology  	 NNP	I-NP
of  	of  	 IN	I-NP
infectious  	infectious  	 JJ	I-NP
endocarditis  	endocarditis  	 NN	I-NP
has  	has  	 VBZ	O
changed  	changed  	 VBN	O
in  	in  	 IN	O
last  	last  	 JJ	O
decades 	decades 	 NNS	O
,  	,  	 ,	O
endocarditis  	endocarditis  	 VBD	O
associated  	associated  	 VBN	O
to  	to  	 TO	O
hospital  	hospital  	 NN	B-NP
practices 	practices 	 NNS	I-NP
,  	,  	 ,	O
sustained  	sustained  	 VBN	O
by  	by  	 IN	O
multiresistant  	multiresistant  	 JJ	B-NP
pathogens  	pathogens  	 NNS	I-NP
being  	being  	 VBG	O
highly  	highly  	 RB	O
increased 	increased 	 VBN	O
.  	.  	 .	O
In  	In  	 IN	O
particular 	particular 	 JJ	O
,  	,  	 ,	O
methicillin-resistant  	methicillin-resistant  	 JJ	B-NP
staphylococci  	staphylococci  	 NNS	I-NP
( 	( 	 -LRB-	O
MRSA 	MRSA 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
almost  	almost  	 RB	O
resistant  	resistant  	 JJ	O
to  	to  	 TO	O
a  	a  	 DT	O
number  	number  	 NN	O
of  	of  	 IN	O
other  	other  	 JJ	O
antimicrobial  	antimicrobial  	 JJ	B-NP
classes 	classes 	 NNS	I-NP
,  	,  	 ,	O
often  	often  	 RB	O
exhibit  	exhibit  	 VB	O
a  	a  	 DT	O
reduced  	reduced  	 JJ	O
susceptibility  	susceptibility  	 NN	O
to  	to  	 TO	O
vancomycin  	vancomycin  	 VB	O
( 	( 	 -LRB-	O
h-VISA 	h-VISA 	 NNP	B-NP
)  	)  	 -RRB-	O
with  	with  	 IN	O
MICs 	MICs 	 NNP	B-NP
'  	'  	 POS	O
values  	values  	 NNS	O
more  	more  	 RBR	O
e  	e  	 JJ	O
than  	than  	 IN	O
1  	1  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	I-NP
l 	l 	 NN	I-NP
,  	,  	 ,	O
leading  	leading  	 VBG	O
to  	to  	 TO	O
suppose  	suppose  	 VB	O
a  	a  	 DT	O
reduced  	reduced  	 JJ	O
therapeutic  	therapeutic  	 JJ	B-NP
efficacy  	efficacy  	 NN	I-NP
of  	of  	 IN	O
this  	this  	 DT	O
drug 	drug 	 NN	O
.  	.  	 .	O
Thirty-one  	Thirty-one  	 JJ	O
percent  	percent  	 NN	O
of  	of  	 IN	O
MRSA  	MRSA  	 NNP	B-NP
strains  	strains  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
ICE  	ICE  	 NNP	O
study 	study 	 NN	O
,  	,  	 ,	O
which  	which  	 WDT	O
prospectively  	prospectively  	 RB	O
collected  	collected  	 VBN	O
more  	more  	 JJR	O
than  	than  	 IN	O
5000  	5000  	 CD	O
endocarditis 	endocarditis 	 NN	B-NP
,  	,  	 ,	O
were  	were  	 VBD	O
h-VISA 	h-VISA 	 JJ	B-NP
.  	.  	 .	O
Daptomycin  	Daptomycin  	 NNP	B-NP
shows  	shows  	 VBZ	O
a  	a  	 DT	O
rapid  	rapid  	 JJ	B-NP
bactericidal  	bactericidal  	 JJ	I-NP
activity  	activity  	 NN	I-NP
against  	against  	 IN	O
both  	both  	 DT	O
methicillin-susceptible  	methicillin-susceptible  	 JJ	B-NP
staphylococcci  	staphylococcci  	 NNS	I-NP
( 	( 	 -LRB-	O
MSSA 	MSSA 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
MRSA 	MRSA 	 NNP	B-NP
,  	,  	 ,	O
included  	included  	 VBD	O
those  	those  	 DT	O
strains  	strains  	 NNS	O
with  	with  	 IN	O
reduced  	reduced  	 JJ	O
susceptibility  	susceptibility  	 NN	O
to  	to  	 TO	O
vancomycin 	vancomycin 	 VB	O
.  	.  	 .	O
Daptomycin  	Daptomycin  	 NNP	B-NP
shows  	shows  	 VBZ	O
a  	a  	 DT	O
good  	good  	 JJ	O
therapeutic  	therapeutic  	 JJ	B-NP
efficacy  	efficacy  	 NN	I-NP
in  	in  	 IN	O
staphylococcal  	staphylococcal  	 JJ	B-NP
endocarditis 	endocarditis 	 NN	I-NP
:  	:  	 :	O
MRSA  	MRSA  	 NNP	B-NP
71 	71 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
MSSA  	MSSA  	 NNP	B-NP
75 	75 	 CD	O
% 	% 	 NN	O
.  	.  	 .	O
These  	These  	 DT	O
data  	data  	 NNS	O
suggest  	suggest  	 VBP	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
daptomycin  	daptomycin  	 NN	B-NP
as  	as  	 IN	O
initial  	initial  	 JJ	O
therapy  	therapy  	 NN	O
for  	for  	 IN	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
staphylococcal  	staphylococcal  	 JJ	B-NP
endocarditis 	endocarditis 	 NN	I-NP
,  	,  	 ,	O
independently  	independently  	 RB	O
from  	from  	 IN	O
methcillin  	methcillin  	 JJ	B-NP
susceptibility 	susceptibility 	 NN	I-NP
.  	.  	 .	O
Some  	Some  	 DT	O
experimental  	experimental  	 JJ	B-NP
data  	data  	 NNS	I-NP
showed  	showed  	 VBD	O
that  	that  	 DT	O
daptomycin  	daptomycin  	 JJ	B-NP
efficacy  	efficacy  	 NN	I-NP
can  	can  	 MD	O
diminish 	diminish 	 VB	O
,  	,  	 ,	O
if  	if  	 IN	O
it  	it  	 PRP	O
is  	is  	 VBZ	O
used  	used  	 VBN	O
as  	as  	 IN	O
a  	a  	 DT	O
rescue  	rescue  	 NN	B-NP
therapy  	therapy  	 NN	I-NP
after  	after  	 IN	O
vancomycin  	vancomycin  	 JJ	B-NP
failure 	failure 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
thickness  	thickness  	 NN	O
of  	of  	 IN	O
bacterial  	bacterial  	 JJ	B-NP
cell-wall  	cell-wall  	 NN	I-NP
recognized  	recognized  	 VBN	O
in  	in  	 IN	O
h-VISA  	h-VISA  	 JJ	B-NP
strains  	strains  	 NNS	I-NP
can  	can  	 MD	O
represent  	represent  	 VB	O
a  	a  	 DT	O
physical  	physical  	 JJ	O
and  	and  	 CC	O
electrical  	electrical  	 JJ	B-NP
barrier  	barrier  	 NN	I-NP
to  	to  	 TO	O
reach  	reach  	 VB	O
both  	both  	 PDT	O
the  	the  	 DT	O
vancomycin  	vancomycin  	 NN	B-NP
and  	and  	 CC	O
daptomycin  	daptomycin  	 JJ	B-NP
target  	target  	 NN	I-NP
site 	site 	 NN	I-NP
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
reduced  	reduced  	 JJ	O
efficacy  	efficacy  	 NN	O
of  	of  	 IN	O
daptomycin  	daptomycin  	 NNS	B-NP
following  	following  	 VBG	O
vancomycin  	vancomycin  	 JJ	B-NP
exposure  	exposure  	 NN	I-NP
is  	is  	 VBZ	O
an  	an  	 DT	O
extremely  	extremely  	 RB	O
rare  	rare  	 JJ	O
event  	event  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
practice 	practice 	 NN	I-NP
.  	.  	 .	O
It  	It  	 PRP	O
is  	is  	 VBZ	O
preferrable  	preferrable  	 VBN	O
to  	to  	 TO	O
use  	use  	 VB	O
daptomycin  	daptomycin  	 VBN	O
as  	as  	 IN	O
first  	first  	 JJ	O
line  	line  	 NN	B-NP
therapy 	therapy 	 NN	I-NP
,  	,  	 ,	O
at  	at  	 IN	O
a  	a  	 DT	O
proper  	proper  	 JJ	O
dosage 	dosage 	 NN	O
.  	.  	 .	O
As  	As  	 RB	O
far  	far  	 RB	O
as  	as  	 IN	O
endocarditis  	endocarditis  	 NN	B-NP
is  	is  	 VBZ	O
concerned 	concerned 	 VBN	O
,  	,  	 ,	O
recent  	recent  	 JJ	O
data  	data  	 NNS	O
proved  	proved  	 VBD	O
the  	the  	 DT	O
excellent  	excellent  	 JJ	O
daptomycin  	daptomycin  	 JJ	B-NP
tolerability 	tolerability 	 NN	I-NP
,  	,  	 ,	O
with  	with  	 IN	O
dosages  	dosages  	 VBG	O
up  	up  	 RP	O
to  	to  	 TO	O
8-10  	8-10  	 FW	O
mg 	mg 	 FW	B-NP
/ 	/ 	 FW	I-NP
kg 	kg 	 FW	I-NP
/ 	/ 	 FW	I-NP
die 	die 	 FW	I-NP
.  	.  	 .	O
During  	During  	 IN	O
the  	the  	 DT	O
treatment 	treatment 	 NN	O
,  	,  	 ,	O
CPK  	CPK  	 NNP	B-NP
values  	values  	 NNS	O
must  	must  	 MD	O
be  	be  	 VB	O
always  	always  	 RB	O
monitored 	monitored 	 VBN	O
.  	.  	 .	O
For  	For  	 IN	O
endocarditis  	endocarditis  	 VBG	O
sustained  	sustained  	 VBN	O
by  	by  	 IN	O
vancomycin-resistant  	vancomycin-resistant  	 JJ	B-NP
enterococci 	enterococci 	 NN	I-NP
,  	,  	 ,	O
therapeutic  	therapeutic  	 JJ	B-NP
choices  	choices  	 NNS	I-NP
are  	are  	 VBP	O
based  	based  	 VBN	O
on  	on  	 IN	O
linezolid  	linezolid  	 NN	B-NP
or  	or  	 CC	O
ampicillin-ceftriaxone  	ampicillin-ceftriaxone  	 JJ	B-NP
combination  	combination  	 NN	I-NP
therapy 	therapy 	 NN	I-NP
.  	.  	 .	O
Daptomycin  	Daptomycin  	 NNP	B-NP
alone 	alone 	 RB	O
,  	,  	 ,	O
or  	or  	 CC	O
in  	in  	 IN	O
association  	association  	 NN	O
with  	with  	 IN	O
gentamycin  	gentamycin  	 NN	B-NP
and  	and  	 CC	O
rifampin 	rifampin 	 NN	B-NP
,  	,  	 ,	O
can  	can  	 MD	O
represent  	represent  	 VB	O
a  	a  	 DT	O
promising  	promising  	 JJ	O
therapeutic  	therapeutic  	 JJ	B-NP
alternative 	alternative 	 NN	I-NP
.  	.  	 .	O
